SCHEMBL3404358

SCHEMBL3404358

CC(C)N(C(=O)Nc1ccc(-c2cc(O)no2)cc1)c1ccc2nc(S)sc2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.37
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
APAF1 O14727 1/20 0.33
TDP2 O95551 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
CASP3 P42574 1/20 0.33
BLM P54132 1/20 0.33
CASP6 P55212 1/20 0.33
ATM Q13315 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
CDC7 O00311 1/20 0.32
PLK4 O00444 1/20 0.32
IKBKB O14920 1/20 0.32
PDPK1 O15530 1/20 0.32
DYRK3 O43781 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405750 0.88 NPC1 (0.35) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL3405134 0.87 EPHX2 (0.33) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL3404648 0.86 HDAC4 (0.34) MAPTATMTSHR
SCHEMBL3410003 0.85 MAPT (0.35) MAPTALDH1A1MEN1KMT2ACDC7
SCHEMBL2867241 0.84 MAPT (0.43) MAPTALDH1A1MEN1KMT2AHPGD
SCHEMBL3407752 0.84 THRB (0.36) MAPTALDH1A1HSD17B10HPGDTP53
SCHEMBL3408188 0.80 MAPT (0.39) MAPTALDH1A1MEN1KMT2AAPAF1
SCHEMBL3408842 0.79 HDAC3 (0.33) MAPT
SCHEMBL3407820 0.79 HDAC4 (0.34) ALDH1A1CASP3SENP8SENP7SENP6
SCHEMBL3403914 0.79 MAPT (0.38) MAPTALDH1A1MEN1KMT2AAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370260-B1 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-11-24 EP claimed
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-05-13 US claimed
EP-1370260-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP claimed
WO-2002066035-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators ME1, ME3, ME2 MAPT 3030/4885ALDH1A1 146/4885MEN1 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.